Elon Musk’s brain-computer interface company Neuralink is preparing for a major expansion, announcing plans to begin high-volume production of its brain implant devices and transition to a fully automated surgical procedure by 2026. The announcement was made by Musk in a post on the social media platform X, highlighting the company’s long-term vision to scale its neurotechnology and make implantation faster, safer, and more accessible.
Neuralink’s brain implant technology is designed to help people with severe neurological conditions, including spinal cord injuries and paralysis, by enabling direct communication between the brain and external devices. The implant allows users to control digital tools using their thoughts, opening new possibilities for restoring independence and improving quality of life. According to previously shared updates, the first patient implanted with the device has successfully used it to play video games, browse the internet, post on social media, and control a laptop cursor without physical movement.
The company began human trials of its brain-computer interface in 2024 after resolving safety concerns raised by the U.S. Food and Drug Administration. The FDA had initially rejected Neuralink’s application in 2022, citing potential risks, but later approved the trials after additional safeguards were implemented. This marked a significant milestone for the company and the broader neurotechnology industry.
In September, Neuralink revealed that 12 people worldwide with severe paralysis had already received its brain implants. These individuals were reportedly using the technology to control both digital and physical tools purely through thought, demonstrating the real-world potential of brain-computer interfaces. The company has also attracted strong investor interest, securing $650 million in a funding round completed in June, further supporting its research, development, and manufacturing goals.
While Neuralink did not immediately respond to a request for comment, Musk’s statement suggests the company is moving toward large-scale deployment. If successful, high-volume production and fully automated surgical implantation could significantly accelerate adoption of brain implant technology, positioning Neuralink as a leader in the rapidly evolving field of neural interfaces and medical innovation.


Apple Unveils Enhanced Apple Intelligence and Next-Generation Siri at WWDC 2026
SpaceX IPO Demand Surges Past $250 Billion Ahead of Historic Market Debut
Alibaba Offers $1.5 Billion to Acquire Grocery Delivery Platform Pupu
China vs. NASA: The New Moon Race and What's at Stake by 2030
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern
Meta AI Strategy Faces Challenges as Zuckerberg Admits Mistakes in Internal Memo
Quantinuum Raises $1.68 Billion in Upsized Nasdaq IPO Amid Growing Quantum Computing Demand
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
SpaceX IPO Set for Explosive Debut as Valuation Tops $2.2 Trillion
Neuralink Expands Brain Implant Trials with 12 Global Patients
EngineAI Files for Hong Kong IPO Amid Rising Demand for AI and Robotics Stocks
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
CrowdStrike Beats Q1 FY2027 Expectations, Raises Outlook Despite After-Hours Stock Decline
Wizz Air Beats Profit Forecast as Cost Controls Offset Industry Challenges
Meta Partners With Reliance to Launch First AI-Powered Data Center in India 



